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Background/aim:COVID-19 has become the biggest health problem of this century. It has been hypothesized that immunity against
hepatitis A virus (HAV) may provide protection from COVID- 19.
Materials and methods: As of 10June 2020, the infection had spread to 213 countries, with 7.3 million people infected and 413,733
dead. This data was combined with the World Health Organization susceptibility classification on the worldwide prevalence of HAV, and
the relationship between HAV susceptibility and COVID-19 mortality were analyzed.
Results: When the data from 213 countries were analyzed, it was found that there was a significant increasing trend in COVID-19
mortality rates by HAV susceptibility (P <0.001). Using a cut-off of 200/million population, the mortality risk associated with living in
a more susceptible country (medium/high) was 27.8 times higher (95% CI for OR: 3.6–213.2)
Conclusion: The results of this study showed that, despite confounding factors in different countries, hepatitis A susceptibility of the
population may have been correlated with COVID-19 mortality. This observation needs to be confirmed by further studies.
Key words: Hepatitis A, COVID-19, vaccine, mortality

To the Editor,
The COVID-19 pandemic has become the biggest
health problem of this century. Several factors have caused
the impact of the disease to vary among countries. It had
been previously hypothesized that immunity against
hepatitis A virus (HAV) may provide protection from
COVID-19 [1], and herein, it was aimed to support this
hypothesis with data.
As of 10 June 2020, the infection had spread to 213
countries, with 7.3 million people infected and 413,733
dead 1. This publicly available data was combined with the
World Health Organization susceptibility classification
published in 2009 on the worldwide prevalence of hepatitis
A [2]. Figures 1 and 2 show the significant increasing trend
in COVID-19 mortality rates by HAV susceptibility (P
<0.001, Jonckheere–Terpstra test). Moreover, using a cutoff of 200/million population,the mortality risk associated
with living in a more susceptible country (medium/high)
was 27.8 times higher (95%CI for OR: 3.6–213.2) (Table).
Several known facts supported the hypothesis. Although
children constitute a very significant risk group for several
respiratory viruses, they seemed to have been spared from
1

COVID-19. The immunity of children against HAV (a virus
with similar taxonomy to coronaviruses), acquired either
by vaccination in developed countries or by infection in
underdeveloped countries, may have contributed to this
protection. The loss of immunity to HAV as the result of
aging may have led to an increased COVID-19 morbidity
in the elderly.
The Diamond Princess ship experience also supported
this theory. Of the 3711 passengers and crew members,
58% were over the age of 60. In total, 712 of the passengers
were infected and 13 died (1.8% fatality).The asymptomatic
infection rate was 57% in elderly individuals over the age of
60 [3]. Thus far, the reason for this extremely low fatality and
unusually high asymptomatic infection rate has not been
explained. The Centers for Disease Control and Prevention
recommendation that all susceptible people traveling for
any purpose, frequency, or duration to countries with high
or intermediate HAV endemicity should be vaccinated
before departure, which all notable cruise lines to Asia
comply with, may have been one explanation [4].
We are aware that this ecological analysis is far from
pointing to a causal relationship. However, given the

Worldometer (2020).Coronavirus COVID-19 Statistics [online]. Website https://www.worldometers.info/coronavirus/ [accessed 10 June 2020].
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Figure 1. Box plots showing the increasing mortality trend by increasing HAV susceptibility in the 213 countries affected by the virus.
If the data is limited to countries with more than 1 million population, 5 million population and 5000 tests/1 million population,
the associated risk with increasing HAV susceptibility is even stronger (Supplementary file). The analyses do not take into account
several confounding factors that may affect the death rates, including, but not limited to, socioeconomic status, accessibility of health
services, and government pandemic policies. For example, Australia, New Zealand, Singapore, Japan, and South Korea are countries
with excellent policies against the COVID-19 pandemic and have low mortality rates in the high susceptibility group. In contrast,
countries with serious socioeconomic problems, such as Ecuador and Peru, have high mortality rates in the low susceptibility group.
These are examples of a possible bias towards the null, while it is accepted that other sources of bias away from the null may exist.

Figure 2. Increased risk of high mortality by increasing HAV susceptibility. High mortality is defined as having a mortality rate of more
than 7/million (the median of 213 countries). The plotted ORs were from the univariate logistic regression model. The reference is the
very low susceptibility group. Countries in the medium and high HAV-susceptible groups may be observed to have 7–8 times higher
risk when compared to the reference (very low susceptibility) group.
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Table. Risk associated with high or medium HAV susceptibility in the countries by subgroups.

All countries
(N = 213)

Mortality rate

Mortality rate

<200 per ≥200 per
OR (95% CI)
million million

<7/
≥7/
OR (95%CI)
million million

All
countries

Very low, low, or low-medium 121

1

Reference

80

42

Reference

122

Medium or high

74

17

27.8 (3.6–213.2)

26

65

4.76 (2.6–8.6)

91

Total

195

18

106

107

213

Countries with Very low, low, or low-medium 106
>1 million
Medium or high
38
population
Total
144

1

Reference

70

37

Reference

11

30.7 (3.8–245.7)

8

41

9.69 (4.1–22.8) 49

78

78

Countries with Very low, low, or low-medium
>5 million
Medium or high
population
Total
Countries
Very low, low, or low-medium
with >5000
Medium or high
tests/1 million
Total
population

85

1

Reference

58

28

Reference

26

10

32.6 (4.00–267.5) 6

30

10.4 (3.9–27.8) 36

111

11

64

58

50

1

Reference

26

25

Reference

51

61

17

13.9 (1.8–108.4)

18

60

3.5 (1.6–7.4)

78

111

18

44

85

12

107
156
86
122

129

Association of high HAV susceptibility and high COVID-19 mortality holds in different subgroups. Two cut-offs were used: 7 (the
median) and 200 (derived from the receiver operator curve analysis). OR: odds ratio showing risk in medium, high group when
compared to the very low, low, low-medium group.

simplicity and the very low risk/benefit ratio of the
preventive measures, it is far from being negligible.
We are proceeding with detailed analyses, to try and
find confounders that may have led to this association,
but with this letter, we are urging the medical community
to help in challenging this hypothesis. If confirmed, the
consequences of this simple discovery will be enormous.
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